Liu Lei, Wang Xinyu, Guo Dekai, Ma Ruirui, Gong Haibing, Wang Congjun
Department of Digestive Surgery, Songjiang Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, 201600, China.
Division of Biology, University of California San Diego, 9500 Gilman Dr. La Jolla, CA, 92093, USA.
Heliyon. 2024 Sep 6;10(18):e37588. doi: 10.1016/j.heliyon.2024.e37588. eCollection 2024 Sep 30.
Pancreatic cancer is a serious, usually fatal disease and one of the most aggressive malignancies. Research into whether hormone replacement therapy (HRT) might protect against pancreatic cancer has yielded mixed results. This study aimed to investigate the potential association between HRT and the risk of pancreatic cancer in postmenopausal women.
This population-based, retrospective study extracted data from the US National Inpatient Sample (NIS) 2008-2018. Hospitalized females aged ≥55 years were eligible for inclusion. Associations between HRT, other study variables, and pancreatic cancer diagnosis were determined using univariate and multivariable regression analyses.
After 1:4 matching by age, data of postmenopausal women with (n = 35,309) and without (n = 141,236) HRT were included in the analysis. The mean age was 73.4 years. Multivariable analyses showed that women with HRT had significantly decreased odds of pancreatic cancer (adjusted OR [aOR], 0.69, 95 % CI: 0.53-0.90). Compared to patients without HRT, patients with HRT in the 55-64-year-old group (aOR 0.48, 95 % CI: 0.32-0.74), 65-74-year-old group (aOR 0.49, 95 % CI: 0.34-0.71), non-hypertensive group (aOR 0.55, 95 % CI: 0.38-0.79), and non-hyperlipidemia group (aOR 0.59, 95 % CI: 0.42-0.82) had significantly decreased odds of pancreatic cancer.
In US postmenopausal women, HRT is associated with a reduced risk of pancreatic cancer, especially those aged 55-74 year. Further study is needed to clarify the mechanisms underlying the associations.
胰腺癌是一种严重的、通常致命的疾病，也是最具侵袭性的恶性肿瘤之一。关于激素替代疗法（HRT）是否能预防胰腺癌的研究结果不一。本研究旨在调查HRT与绝经后女性患胰腺癌风险之间的潜在关联。
这项基于人群的回顾性研究从2008 - 2018年美国国家住院样本（NIS）中提取数据。年龄≥55岁的住院女性符合纳入标准。使用单变量和多变量回归分析确定HRT、其他研究变量与胰腺癌诊断之间的关联。
按年龄1:4匹配后，纳入分析的有HRT的绝经后女性（n = 35,309）和无HRT的绝经后女性（n = 141,236）的数据。平均年龄为73.4岁。多变量分析显示，接受HRT的女性患胰腺癌的几率显著降低（调整后的比值比[aOR]，0.69，95%置信区间：0.53 - 0.90）。与未接受HRT的患者相比，55 - 64岁组（aOR 0.48，95%置信区间：0.32 - 0.74）、65 - 74岁组（aOR 0.49，95%置信区间：0.34 - 0.71）、非高血压组（aOR 0.55，95%置信区间：0.38 - 0.79）和非高脂血症组（aOR 0.59，95%置信区间：0.42 - 0.82）中接受HRT的患者患胰腺癌的几率显著降低。
在美国绝经后女性中，HRT与患胰腺癌风险降低有关，尤其是55 - 74岁的女性。需要进一步研究以阐明这些关联背后的机制。
